Parents ||| S:0 E:7 ||| NNS
'  ||| S:7 E:9 ||| ''
and  ||| S:9 E:13 ||| CC
Adolescents ||| S:13 E:24 ||| NNP
'  ||| S:24 E:26 ||| POS
Preferences  ||| S:26 E:38 ||| NNPS
for  ||| S:38 E:42 ||| IN
Intensified  ||| S:42 E:54 ||| NNP
or  ||| S:54 E:57 ||| CC
Reduced  ||| S:57 E:65 ||| NNP
Treatment  ||| S:65 E:75 ||| NNP
in  ||| S:75 E:78 ||| IN
Randomized  ||| S:78 E:89 ||| NNP
Lymphoblastic  ||| S:89 E:103 ||| NNP
Leukemia  ||| S:103 E:112 ||| NNP
Trials  ||| S:112 E:119 ||| NNP
When  ||| S:119 E:124 ||| WRB
offered  ||| S:124 E:132 ||| VBN
participation  ||| S:132 E:146 ||| NN
in  ||| S:146 E:149 ||| IN
clinical  ||| S:149 E:158 ||| JJ
trials ||| S:158 E:164 ||| NNS
,  ||| S:164 E:166 ||| ,
families  ||| S:166 E:175 ||| NNS
of  ||| S:175 E:178 ||| IN
children  ||| S:178 E:187 ||| NNS
with  ||| S:187 E:192 ||| IN
cancer  ||| S:192 E:199 ||| NN
face  ||| S:199 E:204 ||| VBP
a  ||| S:204 E:206 ||| DT
delicate  ||| S:206 E:215 ||| JJ
balance  ||| S:215 E:223 ||| NN
between  ||| S:223 E:231 ||| IN
cure  ||| S:231 E:236 ||| NN
and  ||| S:236 E:240 ||| CC
toxicity ||| S:240 E:248 ||| NN
.  ||| S:248 E:250 ||| .
Since  ||| S:250 E:256 ||| IN
parents  ||| S:256 E:264 ||| NNS
and  ||| S:264 E:268 ||| CC
children  ||| S:268 E:277 ||| NNS
may  ||| S:277 E:281 ||| MD
perceive  ||| S:281 E:290 ||| VB
this  ||| S:290 E:295 ||| DT
balance  ||| S:295 E:303 ||| NN
differently ||| S:303 E:314 ||| RB
,  ||| S:314 E:316 ||| ,
this  ||| S:316 E:321 ||| DT
paper  ||| S:321 E:327 ||| NN
explores  ||| S:327 E:336 ||| NN
whether  ||| S:336 E:344 ||| IN
adolescent  ||| S:344 E:355 ||| JJ
patients  ||| S:355 E:364 ||| NNS
have  ||| S:364 E:369 ||| VBP
different  ||| S:369 E:379 ||| JJ
enrollment  ||| S:379 E:390 ||| NN
patterns  ||| S:390 E:399 ||| NNS
compared  ||| S:399 E:408 ||| VBN
to  ||| S:408 E:411 ||| TO
younger  ||| S:411 E:419 ||| JJR
children  ||| S:419 E:428 ||| NNS
in  ||| S:428 E:431 ||| IN
trials  ||| S:431 E:438 ||| NNS
with  ||| S:438 E:443 ||| IN
different  ||| S:443 E:453 ||| JJ
toxicity  ||| S:453 E:462 ||| NN
profiles ||| S:462 E:470 ||| NNS
.  ||| S:470 E:472 ||| .
Age-dependent  ||| S:472 E:486 ||| JJ
participation  ||| S:486 E:500 ||| NN
rates  ||| S:500 E:506 ||| NNS
in  ||| S:506 E:509 ||| IN
three  ||| S:509 E:515 ||| CD
consecutive ||| S:515 E:526 ||| JJ
,  ||| S:526 E:528 ||| ,
randomized  ||| S:528 E:539 ||| JJ
childhood  ||| S:539 E:549 ||| NN
leukemia  ||| S:549 E:558 ||| NN
trials  ||| S:558 E:565 ||| NNS
conducted  ||| S:565 E:575 ||| VBN
by  ||| S:575 E:578 ||| IN
the  ||| S:578 E:582 ||| DT
Nordic  ||| S:582 E:589 ||| NNP
Society  ||| S:589 E:597 ||| NNP
of  ||| S:597 E:600 ||| IN
Paediatric  ||| S:600 E:611 ||| NNP
Haematology  ||| S:611 E:623 ||| NNP
and  ||| S:623 E:627 ||| CC
Oncology  ||| S:627 E:636 ||| NNP
were  ||| S:636 E:641 ||| VBD
evaluated ||| S:641 E:650 ||| VBN
.  ||| S:650 E:652 ||| .
The  ||| S:652 E:656 ||| DT
ALL2000  ||| S:656 E:664 ||| FW
dexamethasone ||| S:664 E:677 ||| FW
/ ||| S:677 E:678 ||| FW
vincristine  ||| S:678 E:690 ||| FW
( ||| S:690 E:691 ||| -LRB-
Dx ||| S:691 E:693 ||| NNP
/ ||| S:693 E:694 ||| NNP
VCR ||| S:694 E:697 ||| NNP
)  ||| S:697 E:699 ||| -RRB-
trial  ||| S:699 E:705 ||| NN
tested  ||| S:705 E:712 ||| VBN
treatment  ||| S:712 E:722 ||| NN
intensifications  ||| S:722 E:739 ||| NN
to  ||| S:739 E:742 ||| TO
improve  ||| S:742 E:750 ||| VB
cure ||| S:750 E:754 ||| NN
,  ||| S:754 E:756 ||| ,
and  ||| S:756 E:760 ||| CC
the  ||| S:760 E:764 ||| DT
back-to-back  ||| S:764 E:777 ||| JJ
ALL2008  ||| S:777 E:785 ||| NNP
6-mercaptopurine  ||| S:785 E:802 ||| NNP
( ||| S:802 E:803 ||| -LRB-
6MP ||| S:803 E:806 ||| NNP
)  ||| S:806 E:808 ||| -RRB-
and  ||| S:808 E:812 ||| CC
ALL2008  ||| S:812 E:820 ||| NNP
PEG-asparaginase  ||| S:820 E:837 ||| NNP
( ||| S:837 E:838 ||| -LRB-
ASP ||| S:838 E:841 ||| NNP
)  ||| S:841 E:843 ||| -RRB-
trials  ||| S:843 E:850 ||| NNS
tested  ||| S:850 E:857 ||| VBN
treatment  ||| S:857 E:867 ||| NN
intensifications  ||| S:867 E:884 ||| NNS
( ||| S:884 E:885 ||| -LRB-
6MP ||| S:885 E:888 ||| NNP
)  ||| S:888 E:890 ||| -RRB-
and  ||| S:890 E:894 ||| CC
toxicity  ||| S:894 E:903 ||| JJ
reduction  ||| S:903 E:913 ||| NN
without  ||| S:913 E:921 ||| IN
compromising  ||| S:921 E:934 ||| JJ
survival  ||| S:934 E:943 ||| NN
( ||| S:943 E:944 ||| -LRB-
ASP ||| S:944 E:947 ||| NNP
) ||| S:947 E:948 ||| -RRB-
.  ||| S:948 E:950 ||| .
Patient  ||| S:950 E:958 ||| JJ
randomization  ||| S:958 E:972 ||| NN
and  ||| S:972 E:976 ||| CC
toxicity  ||| S:976 E:985 ||| JJ
data  ||| S:985 E:990 ||| NNS
were  ||| S:990 E:995 ||| VBD
prospectively  ||| S:995 E:1009 ||| RB
registered  ||| S:1009 E:1020 ||| VBN
by  ||| S:1020 E:1023 ||| IN
the  ||| S:1023 E:1027 ||| DT
treating  ||| S:1027 E:1036 ||| JJ
physicians ||| S:1036 E:1046 ||| NNS
.  ||| S:1046 E:1048 ||| .
Parents  ||| S:1048 E:1056 ||| NNS
of  ||| S:1056 E:1059 ||| IN
young  ||| S:1059 E:1065 ||| JJ
children  ||| S:1065 E:1074 ||| NNS
favored  ||| S:1074 E:1082 ||| VBD
treatment  ||| S:1082 E:1092 ||| NN
intensifications  ||| S:1092 E:1109 ||| NNS
( ||| S:1109 E:1110 ||| -LRB-
Dx ||| S:1110 E:1112 ||| NNP
/ ||| S:1112 E:1113 ||| NNP
VCR ||| S:1113 E:1116 ||| NNP
:  ||| S:1116 E:1118 ||| :
12 ||| S:1118 E:1120 ||| CD
%  ||| S:1120 E:1122 ||| NN
refusal ||| S:1122 E:1129 ||| NN
;  ||| S:1129 E:1131 ||| :
6MP ||| S:1131 E:1134 ||| CD
:  ||| S:1134 E:1136 ||| :
14 ||| S:1136 E:1138 ||| CD
% ||| S:1138 E:1139 ||| NN
;  ||| S:1139 E:1141 ||| :
ASP ||| S:1141 E:1144 ||| NNP
:  ||| S:1144 E:1146 ||| :
21 ||| S:1146 E:1148 ||| CD
% ||| S:1148 E:1149 ||| NN
) ||| S:1149 E:1150 ||| -RRB-
,  ||| S:1150 E:1152 ||| ,
whereas  ||| S:1152 E:1160 ||| IN
parents  ||| S:1160 E:1168 ||| NNS
of  ||| S:1168 E:1171 ||| IN
adolescents  ||| S:1171 E:1183 ||| JJ
favored  ||| S:1183 E:1191 ||| JJ
treatment  ||| S:1191 E:1201 ||| NN
reductions  ||| S:1201 E:1212 ||| NNS
( ||| S:1212 E:1213 ||| -LRB-
Dx ||| S:1213 E:1215 ||| NNP
/ ||| S:1215 E:1216 ||| NNP
VCR ||| S:1216 E:1219 ||| NNP
:  ||| S:1219 E:1221 ||| :
52 ||| S:1221 E:1223 ||| CD
%  ||| S:1223 E:1225 ||| NN
refusal ||| S:1225 E:1232 ||| NN
;  ||| S:1232 E:1234 ||| :
6MP ||| S:1234 E:1237 ||| CD
:  ||| S:1237 E:1239 ||| :
30 ||| S:1239 E:1241 ||| CD
% ||| S:1241 E:1242 ||| NN
;  ||| S:1242 E:1244 ||| :
ASP ||| S:1244 E:1247 ||| NNP
:  ||| S:1247 E:1249 ||| :
8 ||| S:1249 E:1250 ||| CD
% ||| S:1250 E:1251 ||| NN
) ||| S:1251 E:1252 ||| -RRB-
.  ||| S:1252 E:1254 ||| .
Adolescents  ||| S:1254 E:1266 ||| NNP
were  ||| S:1266 E:1271 ||| VBD
more  ||| S:1271 E:1276 ||| RBR
likely  ||| S:1276 E:1283 ||| JJ
to  ||| S:1283 E:1286 ||| TO
refuse  ||| S:1286 E:1293 ||| VB
intensification  ||| S:1293 E:1309 ||| JJ
trials  ||| S:1309 E:1316 ||| NNS
than  ||| S:1316 E:1321 ||| IN
young  ||| S:1321 E:1327 ||| JJ
children  ||| S:1327 E:1336 ||| NNS
( ||| S:1336 E:1337 ||| -LRB-
adjusted  ||| S:1337 E:1346 ||| VBN
ORs  ||| S:1346 E:1350 ||| JJ
6.3 ||| S:1350 E:1353 ||| CD
;  ||| S:1353 E:1355 ||| :
P  ||| S:1355 E:1357 ||| NN
< ||| S:1357 E:1359 ||| SYM
0.01  ||| S:1359 E:1364 ||| CD
[ ||| S:1364 E:1365 ||| -LRB-
Dx ||| S:1365 E:1367 ||| NNP
/ ||| S:1367 E:1368 ||| NNP
VCR ||| S:1368 E:1371 ||| NNP
]  ||| S:1371 E:1373 ||| -RRB-
and  ||| S:1373 E:1377 ||| CC
2.1 ||| S:1377 E:1380 ||| CD
;  ||| S:1380 E:1382 ||| :
P  ||| S:1382 E:1384 ||| NN
=  ||| S:1384 E:1386 ||| SYM
0.04  ||| S:1386 E:1391 ||| FW
[ ||| S:1391 E:1392 ||| -LRB-
6MP ||| S:1392 E:1395 ||| NNP
] ||| S:1395 E:1396 ||| -RRB-
) ||| S:1396 E:1397 ||| -RRB-
.  ||| S:1397 E:1399 ||| .
Adolescents  ||| S:1399 E:1411 ||| NNP
were  ||| S:1411 E:1416 ||| VBD
less  ||| S:1416 E:1421 ||| RBR
likely  ||| S:1421 E:1428 ||| JJ
to  ||| S:1428 E:1431 ||| TO
refuse  ||| S:1431 E:1438 ||| VB
the  ||| S:1438 E:1442 ||| DT
ASP  ||| S:1442 E:1446 ||| NNP
trial ||| S:1446 E:1451 ||| NN
,  ||| S:1451 E:1453 ||| ,
with  ||| S:1453 E:1458 ||| IN
varying  ||| S:1458 E:1466 ||| VBG
effect  ||| S:1466 E:1473 ||| NN
size  ||| S:1473 E:1478 ||| NN
depending  ||| S:1478 E:1488 ||| VBG
on  ||| S:1488 E:1491 ||| IN
the  ||| S:1491 E:1495 ||| DT
length  ||| S:1495 E:1502 ||| NN
of  ||| S:1502 E:1505 ||| IN
the  ||| S:1505 E:1509 ||| DT
preceding  ||| S:1509 E:1519 ||| JJ
consolidation  ||| S:1519 E:1533 ||| NN
treatment  ||| S:1533 E:1543 ||| NN
( ||| S:1543 E:1544 ||| -LRB-
adjusted  ||| S:1544 E:1553 ||| VBN
OR  ||| S:1553 E:1556 ||| NNP
for  ||| S:1556 E:1560 ||| IN
median  ||| S:1560 E:1567 ||| JJ
consolidation  ||| S:1567 E:1581 ||| NN
length  ||| S:1581 E:1588 ||| NN
0.15 ||| S:1588 E:1592 ||| CD
;  ||| S:1592 E:1594 ||| :
P  ||| S:1594 E:1596 ||| NN
=  ||| S:1596 E:1598 ||| SYM
0.01 ||| S:1598 E:1602 ||| CD
) ||| S:1602 E:1603 ||| -RRB-
.  ||| S:1603 E:1605 ||| .
Younger  ||| S:1605 E:1613 ||| JJR
children  ||| S:1613 E:1622 ||| NNS
participated  ||| S:1622 E:1635 ||| VBD
more  ||| S:1635 E:1640 ||| RBR
frequently  ||| S:1640 E:1651 ||| RB
in  ||| S:1651 E:1654 ||| IN
only  ||| S:1654 E:1659 ||| JJ
6MP  ||| S:1659 E:1663 ||| NN
than  ||| S:1663 E:1668 ||| IN
in  ||| S:1668 E:1671 ||| IN
only  ||| S:1671 E:1676 ||| JJ
ASP  ||| S:1676 E:1680 ||| NNP
( ||| S:1680 E:1681 ||| -LRB-
14 ||| S:1681 E:1683 ||| CD
%  ||| S:1683 E:1685 ||| NN
vs.  ||| S:1685 E:1689 ||| IN
5 ||| S:1689 E:1690 ||| CD
% ||| S:1690 E:1691 ||| NN
) ||| S:1691 E:1692 ||| -RRB-
,  ||| S:1692 E:1694 ||| ,
and  ||| S:1694 E:1698 ||| CC
adolescents  ||| S:1698 E:1710 ||| FW
vice  ||| S:1710 E:1715 ||| FW
versa  ||| S:1715 E:1721 ||| FW
( ||| S:1721 E:1722 ||| -LRB-
2 ||| S:1722 E:1723 ||| CD
%  ||| S:1723 E:1725 ||| NN
vs.  ||| S:1725 E:1729 ||| IN
17 ||| S:1729 E:1731 ||| CD
% ||| S:1731 E:1732 ||| NN
;  ||| S:1732 E:1734 ||| :
P  ||| S:1734 E:1736 ||| NN
=  ||| S:1736 E:1738 ||| SYM
0.001 ||| S:1738 E:1743 ||| CD
) ||| S:1743 E:1744 ||| -RRB-
.  ||| S:1744 E:1746 ||| .
Parents ||| S:1746 E:1753 ||| NNS
'  ||| S:1753 E:1755 ||| ''
and  ||| S:1755 E:1759 ||| CC
adolescents ||| S:1759 E:1770 ||| NN
'  ||| S:1770 E:1772 ||| POS
divergent  ||| S:1772 E:1782 ||| JJ
inclinations  ||| S:1782 E:1795 ||| NN
toward  ||| S:1795 E:1802 ||| IN
intensified  ||| S:1802 E:1814 ||| NN
or  ||| S:1814 E:1817 ||| CC
reduced  ||| S:1817 E:1825 ||| JJ
therapy  ||| S:1825 E:1833 ||| NN
emphasize  ||| S:1833 E:1843 ||| VBD
the  ||| S:1843 E:1847 ||| DT
necessity  ||| S:1847 E:1857 ||| NN
of  ||| S:1857 E:1860 ||| IN
actively  ||| S:1860 E:1869 ||| RB
involving  ||| S:1869 E:1879 ||| VBG
adolescents  ||| S:1879 E:1891 ||| NNS
in  ||| S:1891 E:1894 ||| IN
the  ||| S:1894 E:1898 ||| DT
informed  ||| S:1898 E:1907 ||| JJ
consent  ||| S:1907 E:1915 ||| NN
process ||| S:1915 E:1922 ||| NN
,  ||| S:1922 E:1924 ||| ,
which  ||| S:1924 E:1930 ||| WDT
should  ||| S:1930 E:1937 ||| MD
also  ||| S:1937 E:1942 ||| RB
address  ||| S:1942 E:1950 ||| VB
motives  ||| S:1950 E:1958 ||| NNS
for  ||| S:1958 E:1962 ||| IN
trial  ||| S:1962 E:1968 ||| NN
participation ||| S:1968 E:1981 ||| NN
.  ||| S:1981 E:1983 ||| .
